Table_1_In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A Euro.docx (14.59 kB)

Table_1_In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study.docx

dataset

posted on 2022-05-16, 04:34 authored by Guillermo Quindós, Katherine Miranda-Cadena, Rosario San-Millán, Katyna Borroto-Esoda, Emilia Cantón, María José Linares-Sicilia, Axel Hamprecht, Isabel Montesinos, Anna Maria Tortorano, Anna Prigitano, Matxalen Vidal-García, Cristina Marcos-Arias, Andrea Guridi, Ferran Sanchez-Reus, Jesús Machuca-Bárcena, Manuel Antonio Rodríguez-Iglesias, Estrella Martín-Mazuelos, Carmen Castro-Méndez, Leyre López-Soria, Alba Ruiz-Gaitán, Marcelo Fernandez-Rivero, Damaris Lorenzo, Javier Capilla, Antonio Rezusta, Javier Pemán, Josep Guarro, Joana Pereira, Célia Pais, Orazio Romeo, Guillermo Ezpeleta, Nerea Jauregizar, David Angulo, Elena Eraso

Background

Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis.

Objective

The aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida.

Methods

Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated.

Results

Ibrexafungerp MICs ranged from 0.016 to ≥8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016–0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06–≥8 mg/L). Modal MICs/MIC₅₀s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) C. parapsilosis, 4 (5%) C. glabrata, and 1 (2.5%) C. tropicalis.

Conclusion

Ibrexafungerp showed a potent in vitro activity against Candida.